# A Study of Xevinapant (Debio 1143) in Combination With Platinum-Based Chemotherapy and Standard Fractionation Intensity-Modulated Radiotherapy in Participants With Locally Advanced Squamous Cell Carcinoma of the Head and Neck, Suitable for Definitive Chemoradiotherapy (TrilynX)

> **NCT04459715** · PHASE3 · TERMINATED · sponsor: **EMD Serono Research & Development Institute, Inc.** · enrollment: 730 (actual)

## Conditions studied

- Squamous Cell Carcinoma of the Head and Neck

## Interventions

- **DRUG:** Xevinapant (Debio 1143)
- **DRUG:** Cisplatin
- **RADIATION:** Intensity Modulation Radiation Therapy (IMRT)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04459715
- **Lead sponsor:** EMD Serono Research & Development Institute, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-08-07
- **Primary completion:** 2024-09-18
- **Final completion:** 2024-09-18
- **Target enrollment:** 730 (ACTUAL)
- **Why stopped:** Study has crossed the pre-defined futility boundary at the Interim Analysis.
- **Last updated:** 2025-10-08

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04459715

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04459715, "A Study of Xevinapant (Debio 1143) in Combination With Platinum-Based Chemotherapy and Standard Fractionation Intensity-Modulated Radiotherapy in Participants With Locally Advanced Squamous Cell Carcinoma of the Head and Neck, Suitable for Definitive Chemoradiotherapy (TrilynX)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04459715. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*